RESUMEN
Introducción: la piomiositis (PMS) es una infección bacteriana aguda o subaguda del músculo esquelético. Entidad rara en pediatría, suele acompañarse de la formación de abscesos. Se presenta más frecuentemente en preescolares de sexo masculino, afectando mayoritariamente a extremidades y región pélvica. La manifestación multifocal es frecuente. El principal agente etiológico es Staphylococcus aureus. Caso clínico: 3 años, sexo masculino, sano. Consulta por fiebre continua de hasta 39 ºC de seis días de evolución, dolor de ambos miembros inferiores a predominio izquierdo, cojera y repercusión general. Examen físico: tumoración en muslo izquierdo de límites difusos de 13 x 5 cm, lisa, firme, impresiona adherida a planos musculares, dolorosa. Sin elementos fluxivos en la piel. Ecografía de partes blandas: aumento de tejidos blandos de la extremidad. Resonancia magnética (RM): abscesos que comprometen logia de los aductores del miembro izquierdo, el vasto externo del muslo derecho, musculatura paravertebral lumbar izquierda y cérvico-torácica izquierda. Tratamiento: drenaje, requiere de múltiples limpiezas quirúrgicas y antibioticoterapia prolongada. Cultivo de la lesión: Staphylococcus aureus meticilino resistente (SAMR). Buena evolución clínica e imagenológica. Discusión: la PMS ha presentado una incidencia creciente con la aparición del SAMR. La ecografía es un método adecuado para realizar diagnóstico local. La experiencia en la interpretación de la RM permite pesquisar el compromiso multifocal, identificando focos sin traducción clínica. La antibioticoterapia y el drenaje quirúrgico son los pilares del tratamiento. El pronóstico es bueno en la mayoría de los casos.
Introduction: pyomyositis (PMS) is an acute or subacute bacterial infection of the skeletal muscle. It is a rare infection in pediatrics, and it is usually accompanied by abscess formation. It occurs more frequently in male preschoolers, mostly affecting the extremities and pelvic region. The multifocal manifestation is frequent. The main etiological agent is Staphylococcus aureus. Clinical case: 3 year-old, male, healthy patient. He consulted for continuous fever of up to 39ºC of 6 days of evolution, pain in both lower limbs predominantly on the left, lameness and general repercussions. Physical examination: a 13 x 5 cm tumor in the left thigh with diffuse limits, smooth, firm, adhered to muscle layers, painful. Without fluxive elements on the skin. Soft tissue ultrasound: enlargement of the soft tissues of the extremity. Magnetic resonance imaging (MRI): abscesses involving the adductor lodge of the left limb, the vastus lateralis of the right thigh, left lumbar paravertebral musculature and left cervical-thoracic musculature. Treatment: drainage, requires multiple surgical cleanings and prolonged antibiotic therapy. Culture of the lesion: methicillin-resistant Staphylococcus Aureus (MRSA). Good clinical and imaging evolution. Discussion: PMS has had an increasing incidence with the appearance of MRSA. Ultrasound is a suitable method for local diagnosis. Experience in the interpretation of MRI has enabled us to research multifocal involvement, identifying unobserved foci during clinical check-up. Antibiotic therapy and surgical drainage are the main treatments. The prognosis is good in most cases.
Introdução: Ia Piomiosite (TPM) é uma infecção bacteriana aguda ou subaguda do músculo esquelético. É uma entidade rara em pediatria, costuma vir acompanhada de formação de abscessos. Ocorre com maior frequência em pré-escolares do sexo masculino, afetando principalmente as extremidades e a região pélvica. A manifestação multifocal é comum. O principal agente etiológico é o Staphylococcus aureus. Caso clínico: paciente 3 anos, sexo masculino, hígido. Consulta por febre contínua de até 39ºC há 6 dias, dor em ambos os membros inferiores predominantemente esquerdo, claudicação e repercussão geral. Exame físico: tumor na coxa esquerda com limites difusos de 13 x 5 cm, liso, firme, aparentemente aderido aos planos musculares, doloroso. Sem elementos fluidos na pele. Ultrassonografia de tecidos moles: aumento dos tecidos moles da extremidade. Ressonância magnética (RM): abscessos envolvendo o alojamento adutor do membro esquerdo, vasto lateral da coxa direita, músculos paravertebrais lombares esquerdos e cérvico-torácicos esquerdos. Tratamento: drenagem, requer múltiplas limpezas cirúrgicas e antibioticoterapia prolongada. Cultura da lesão: Staphylococcus aureus resistente à meticilina (MRSA). Boa evolução clínica e imagiológica. Discussão: a TPM tem tido uma incidência crescente com o aparecimento do MRSA. A ultrassonografia é um método adequado para diagnóstico local. A experiência na interpretação de ressonância magnética permite-nos investigar o envolvimento multifocal, identificando focos sem tradução clínica. A antibioticoterapia e a drenagem cirúrgica são os pilares do tratamento. O prognóstico é bom na maioria dos casos.
Asunto(s)
Humanos , Masculino , Preescolar , Infecciones Estafilocócicas/diagnóstico , Infecciones Estafilocócicas/tratamiento farmacológico , Muslo/microbiología , Drenaje , Piomiositis/terapia , Piomiositis/diagnóstico por imagen , Músculos Paraespinales/microbiología , Clindamicina/administración & dosificación , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Antibacterianos/administración & dosificaciónAsunto(s)
Humanos , Masculino , Adolescente , Estenosis de la Válvula Pulmonar/etiología , Estenosis de la Válvula Pulmonar/diagnóstico por imagen , Linfoma no Hodgkin/complicaciones , Linfoma no Hodgkin/diagnóstico , Estenosis de la Válvula Pulmonar/congénito , Toracoscopía/métodos , Dolor en el Pecho/complicaciones , Ecocardiografía/métodos , Radiografía Torácica/métodos , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Quimioterapia/métodos , Disnea/complicaciones , Neoplasias/clasificaciónRESUMEN
Paracoccidioidomycosis (PCM) is a systemic mycosis caused by the Paracoccidioides genus. Most of the patients with chronic form present sequelae, like pulmonary fibrosis, with no effective treatment, leading to impaired lung functions. In the present study, we aimed to investigate the antifibrotic activity of three compounds: pentoxifylline (PTX), azithromycin (AZT), and thalidomide (Thal) in a murine model of pulmonary PCM treated with itraconazole (ITC) or cotrimoxazole (CMX). BALB/c mice were inoculated with P. brasiliensis (Pb) by the intratracheal route and after 8 weeks, they were submitted to one of the following six treatments: PTX/ITC, PTX/CMX, AZT/ITC, AZT/CMX, Thal/ITC, and Thal/CMX. After 8 weeks of treatment, the lungs were collected for determination of fungal burden, production of OH-proline, deposition of reticulin fibers, and pulmonary concentrations of cytokines and growth factors. Pb-infected mice treated with PTX/ITC presented a reduction in the pulmonary concentrations of OH-proline, associated with lower concentrations of interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-ß1 and higher concentrations of IL-10 compared to the controls. The Pb-infected mice treated with AZT/CMX exhibited decreased pulmonary concentrations of OH-proline associated with lower levels of TGF-ß1, and higher levels of IL-10 compared controls. The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-γ and VEGF, and decreased concentrations of IL-6, IL-1ß, IL-17, and TGF-ß1. In conclusion, our findings reinforce the antifibrotic role of PTX only when associated with ITC, and AZT only when associated with CMX, but Thal did not show any action upon addition.
Asunto(s)
Antifúngicos/administración & dosificación , Paracoccidioides/efectos de los fármacos , Paracoccidioidomicosis/tratamiento farmacológico , Fibrosis Pulmonar/tratamiento farmacológico , Animales , Azitromicina/administración & dosificación , Citocinas/análisis , Modelos Animales de Enfermedad , Quimioterapia Combinada , Inmunosupresores/administración & dosificación , Péptidos y Proteínas de Señalización Intercelular/análisis , Itraconazol/administración & dosificación , Masculino , Ratones , Ratones Endogámicos BALB C , Paracoccidioides/crecimiento & desarrollo , Paracoccidioidomicosis/microbiología , Paracoccidioidomicosis/patología , Pentoxifilina/administración & dosificación , Distribución Aleatoria , Talidomida/administración & dosificación , Resultado del Tratamiento , Combinación Trimetoprim y Sulfametoxazol/administración & dosificaciónRESUMEN
INTRODUCTION AND OBJECTIVES: Limited data describe current SBP epidemiology and specific secondary SBP prophylactic regimens, leading to variable prescribing practices. This work aims to compare 90-day and one-year SBP recurrence and mortality based on secondary SBP antibiotic prophylaxis regimens. MATERIALS AND METHODS: We performed a retrospective cohort of patients >18 years with an SBP diagnosis from 2010 to 2015 at two academic institutions. Eligible patients had ascitic PMN counts ≥250cells/mm3 or a positive ascitic culture. Patients were compared based on secondary SBP prophylaxis regimens (i.e., daily, intermittent, or no prophylaxis). RESULTS: Of 791 patients with ascitic fluid samples, 86 patients were included. Antibiotic prophylaxis included daily (n=34), intermittent (n=36), or no prophylaxis (n=16). Nearly half of SBP episodes had a positive ascitic fluid culture; 50% were gram-negative pathogens, and 50% were gram-positive pathogens. Daily and intermittent regimens had similar rates of recurrence at 90-days (19.4% vs. 14.7%, p=0.60) and one-year (33.3% vs. 26.5%, p=0.53). Similarly, mortality did not differ among daily and intermittent regimens at 90-days (32.4% vs. 30.6%, p=0.87) or one-year (67.6% vs. 63.9%, p=0.74). When comparing any prophylaxis vs. no prophylaxis, there were no differences in 90-day or one-year recurrence or mortality. CONCLUSIONS: In patients with a history of SBP, our data indicate similar outcomes with daily, intermittent, or no secondary antibiotic prophylaxis. With available data, including ours, demonstrating a changing epidemiology for SBP pathogens, further data is required to determine if traditional approaches to secondary SBP prophylaxis remain appropriate.
Asunto(s)
Antibacterianos/administración & dosificación , Infecciones Bacterianas/prevención & control , Peritonitis/prevención & control , Anciano , Ascitis/etiología , Líquido Ascítico , Infecciones Bacterianas/etiología , Infecciones Bacterianas/mortalidad , Estudios de Casos y Controles , Ceftizoxima/administración & dosificación , Ceftizoxima/análogos & derivados , Quimioprevención/métodos , Ciprofloxacina/administración & dosificación , Estudios de Cohortes , Femenino , Humanos , Estimación de Kaplan-Meier , Cirrosis Hepática/complicaciones , Modelos Logísticos , Masculino , Persona de Mediana Edad , Moxifloxacino/administración & dosificación , Análisis Multivariante , Peritonitis/etiología , Peritonitis/mortalidad , Modelos de Riesgos Proporcionales , Recurrencia , Estudios Retrospectivos , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , CefpodoximaRESUMEN
Background: The drug supersaturation in the intestinal lumen for few hours could result in high bioavailability. The goal of this study was the development of a supersaturating drug delivery system containing sulfamethoxazole and trimethoprim at fixed dose combination (sulfamethoxazole:trimethoprim 5:1 w/w). Methods: The amorphous solid dispersions were formed at three different proportions containing 30, 50 and 70% of Eudragit EPO in the formulation. Results: The supersaturation state is formed by the amorphous drugs produced by spray drying technique, and the maintenance of this state is due to the chemical interactions between the drugs and the polymer selected, which was observed in the fluorescence interaction studies realized between the drugs and the polymer. The Formulation containing 70% of the polymer was able to produce and maintain the supersaturated state of both drugs for 24 h. Solid state characterization demonstrated the amorphization of the drugs in the solid dispersion and indicated the hydrogen bond formation responsible for the improvement in the apparent solubility. This formulation presented an improved antibacterial activity when compared to the combination of the drugs. Conclusion: For the first time, a supersaturating drug delivery system was developed to the complementary antibacterial drugs. This ternary formulation is a powerful alternative to improve oral absorption of recognized safety drugs, reducing the dose and consequently the antibiotic resistance emergence.
Asunto(s)
Antibacterianos/administración & dosificación , Sistemas de Liberación de Medicamentos , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Administración Oral , Antibacterianos/química , Antibacterianos/farmacología , Química Farmacéutica , Portadores de Fármacos/química , Combinación de Medicamentos , Humanos , Polímeros/química , Ácidos Polimetacrílicos/química , Solubilidad , Factores de Tiempo , Combinación Trimetoprim y Sulfametoxazol/química , Combinación Trimetoprim y Sulfametoxazol/farmacologíaRESUMEN
Paracoccidioidomycosis (PCM) is an endemic systemic mycosis that is of great importance in Latin America. Its occurrence in solid organ transplantation (SOT) is rare, but with high mortality rate. In this report, we describe a case of PCM in a liver transplant recipient 19 months after transplantation. The patient presented with multiple skin abscesses, arthritis, osteolytic lesions, and pulmonary and adrenal involvement. Despite the presence of disseminated disease and the patient's immunosuppressed condition, the patient responded well to prolonged antifungal treatment with no sequelae, thus suggesting that early diagnosis and correct treatment may lead to favorable outcomes in SOT recipients with PCM.
Asunto(s)
Trasplante de Hígado/efectos adversos , Paracoccidioidomicosis/diagnóstico , Paracoccidioidomicosis/tratamiento farmacológico , Receptores de Trasplantes , Anfotericina B/administración & dosificación , Anfotericina B/uso terapéutico , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Antifúngicos/uso terapéutico , Brasil/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Paracoccidioides , Paracoccidioidomicosis/epidemiología , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Combinación Trimetoprim y Sulfametoxazol/uso terapéuticoRESUMEN
This study aimed to evaluate steroid hormones in foals born from mares treated for ascending placentitis with different combinations of trimethoprim-sulfamethoxazole (TMS), flunixin meglumine (FM), long-acting altrenogest (ALT) and estradiol cypionate (ECP) for ten consecutive days, starting two days after experimental induction of placentitis with Streptococcus zooepidemicus. Fourty-six pregnant mares and respective foals were assigned as healthy group (Control, n = 8) or treated groups as follows: TMS+FM (n = 8), TMS+FM+ALT (n = 8), TMS+FM+ALT+ECP (n = 6), TMS+FM+ECP (n = 6) and no treatment (NO TREAT n = 10). At delivery, foals were classified as high-risk or low-risk based on clinical and hematologic findings, and survival rates were recorded during the first week of life for comparisons across groups. Cortisol, progesterone, 17αOHprogesterone, and pregnenolone concentrations were determined via immunoassays in 31 of the 46 foals immediately after foaling (0 h), at 12, 24, 48 h, and seven days post-partum (168h). At birth, serum cortisol concentrations were higher in Control and TMS+FM+ECP foals than in remaining groups (p < 0.05). Foals in TMS+FM+ALT and TMS+FM groups had higher 17αOHprogesterone concentrations at 24 h and 48 h, respectively (p < 0.05). Pregnenolone concentrations were higher in TMS+FM than TMS+FM+ALT+ECP foals at 7 days (p < 0.05). High-risk and non-surviving foals had decreased concentrations of cortisol at parturition, but increased concentrations of progesterone from 0 h to 48 h. Pregnenolone and 17αOHprogesterone concentrations were increased and pregnenolone after 12 h in high-risk and non-surviving foals (p < 0.05). In conclusion, adding ECP to the treatment of experimentally-induced placentitis appears to improve foal viability and endocrine response. Cortisol and progestogen profiles were abnormal in high-risk and non-surviving foals, and those treated with ALT or TMS+FM only.
Asunto(s)
Enfermedades de los Caballos/microbiología , Hidrocortisona/sangre , Enfermedades Placentarias/veterinaria , Pregnenolona/sangre , Progesterona/sangre , Infecciones Estreptocócicas/veterinaria , 17-alfa-Hidroxiprogesterona/sangre , Animales , Animales Recién Nacidos , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Clonixina/administración & dosificación , Clonixina/análogos & derivados , Clonixina/uso terapéutico , Anticonceptivos Femeninos/administración & dosificación , Anticonceptivos Femeninos/uso terapéutico , Estradiol/administración & dosificación , Estradiol/análogos & derivados , Estradiol/uso terapéutico , Femenino , Caballos , Enfermedades Placentarias/microbiología , Embarazo , Progestinas/administración & dosificación , Progestinas/uso terapéutico , Distribución Aleatoria , Streptococcus equi , Acetato de Trembolona/administración & dosificación , Acetato de Trembolona/análogos & derivados , Acetato de Trembolona/uso terapéutico , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Combinación Trimetoprim y Sulfametoxazol/uso terapéuticoRESUMEN
Pneumonia caused by Pneumocystis jirovecii is an uncommon infection in kidney transplant patients that can have an acute and rapid progression to respiratory failure and death. The period of greatest risk occurs in the first six months after the transplant, and it relates to the high doses of immunosuppression drugs required by patients. However, it may occur late, associated with the suspension of prophylaxis with trimethoprim-sulfamethoxazole.We present two cases of renal transplant patients who had severe hypoxemic respiratory failure due to P. jirovecii six years after transplantation. In addition to steroids, they received treatment with trimethoprim-sulfamethoxazole. One patient died, while the other had clinical recovery, with preservation of the renal graft function.
Asunto(s)
Trasplante de Riñón/efectos adversos , Pneumocystis carinii/química , Insuficiencia Respiratoria/complicaciones , Humanos , Pneumocystis carinii/aislamiento & purificación , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Combinación Trimetoprim y Sulfametoxazol/efectos adversosRESUMEN
Resumen La neumonitis por Pneumocystis jirovecii es una infección infrecuente en pacientes con trasplante de riñón, que se presenta de forma aguda y puede progresar rápidamente hasta la insuficiencia respiratoria y la muerte. El período de mayor riesgo es el de los primeros seis meses después del trasplante, y se asocia con las altas dosis de medicamentos inmunosupresores que reciben los pacientes. La condición también puede presentarse de manera tardía, asociada con la suspensión de la profilaxis con trimetoprim-sulfametoxazol. Se reportan dos casos de pacientes con trasplante renal que presentaron insuficiencia respiratoria hipoxémica grave por P. jirovecii pasados seis años del trasplante, y que fueron tratados con trimetoprim-sulfametoxazol y esteroides. Uno de los pacientes murió y el otro se recuperó sin que hubiera efectos en la función del injerto renal.
Abstract Pneumonia caused by Pneumocystis jirovecii is an uncommon infection in kidney transplant patients that can have an acute and rapid progression to respiratory failure and death. The period of greatest risk occurs in the first six months after the transplant, and it relates to the high doses of immunosuppression drugs required by patients. However, it may occur late, associated with the suspension of prophylaxis with trimethoprim-sulfamethoxazole. We present two cases of renal transplant patients who had severe hypoxemic respiratory failure due to P. jirovecii six years after transplantation. In addition to steroids, they received treatment with trimethoprim-sulfamethoxazole. One patient died, while the other had clinical recovery, with preservation of the renal graft function.
Asunto(s)
Humanos , Insuficiencia Respiratoria/complicaciones , Trasplante de Riñón/efectos adversos , Pneumocystis carinii/química , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Combinación Trimetoprim y Sulfametoxazol/efectos adversos , Pneumocystis carinii/aislamiento & purificaciónRESUMEN
PURPOSE: To evaluate intravitreal injections of sulfamethoxazole/trimethoprim in association with dexamethasone for treating toxoplasmic retinochoroiditis. METHODS: Thirteen patients with active, recurrent ocular focal toxoplasmic retinochoroiditis and visual acuity worse than 20/63 in the affected eye were included. Ocular toxoplasmosis was diagnosed according to the classic clinical findings. The primary end point was the change in the final best-corrected visual acuity (BCVA). RESULTS: The intraocular inflammation decreased within 2 weeks after injection in all eyes and resolved in 8 (62%) eyes with only one injection after 30 days; the remaining eyes received two injections. In all eyes, the retinitis was inactive and no patient had decreased early treatment diabetic retinopathy study lines of BCVA at the final examination. CONCLUSION: The combination of intravitreal trimethoprim/sulfamethoxazole and dexamethasone might be an alternative treatment strategy in patients with toxoplasmic retinochoroiditis.
Asunto(s)
Antibacterianos/uso terapéutico , Coriorretinitis/tratamiento farmacológico , Dexametasona/uso terapéutico , Glucocorticoides/uso terapéutico , Toxoplasmosis Ocular/tratamiento farmacológico , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Adulto , Anciano , Antibacterianos/administración & dosificación , Coriorretinitis/diagnóstico , Coriorretinitis/fisiopatología , Terapias Complementarias , Dexametasona/administración & dosificación , Quimioterapia Combinada , Femenino , Glucocorticoides/administración & dosificación , Humanos , Inyecciones Intravítreas , Masculino , Persona de Mediana Edad , Toxoplasmosis Ocular/diagnóstico , Toxoplasmosis Ocular/fisiopatología , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Agudeza Visual , Adulto JovenAsunto(s)
Encefalitis/diagnóstico por imagen , Rombencéfalo/diagnóstico por imagen , Corticoesteroides/administración & dosificación , Ampicilina/administración & dosificación , Encefalitis/tratamiento farmacológico , Femenino , Humanos , Imagen por Resonancia Magnética , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Adulto JovenRESUMEN
We report the case of a 61 year-old male who underwent heart transplantation eight months before developing a systemic condition with central nervous system, lung, kidney, colonic, cutaneous, and hematologic involvement, found to be secondary to a systemic toxoplasmosis despite co-trimoxazole prophylaxis in a previous-to-transplant seronegative patient receiving a heart from a seropositive donor. A review of prophylactic options in our environment is discussed.
Asunto(s)
Trasplante de Corazón , Complicaciones Posoperatorias/etiología , Toxoplasmosis/transmisión , Anticuerpos Antiprotozoarios/sangre , Antivirales/uso terapéutico , Terapia Combinada , Infecciones por Citomegalovirus/tratamiento farmacológico , Infecciones por Citomegalovirus/transmisión , Progresión de la Enfermedad , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Inmunosupresores/efectos adversos , Masculino , Persona de Mediana Edad , Intercambio Plasmático , Complicaciones Posoperatorias/parasitología , Complicaciones Posoperatorias/prevención & control , Recurrencia , Seroconversión , Donantes de Tejidos , Toxoplasmosis/prevención & control , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Viremia/tratamiento farmacológico , Viremia/transmisiónRESUMEN
Resumen Se reporta el caso de un paciente de sexo masculino, de 61 años de edad, quien ocho meses después de someterse a un trasplante de corazón presentó una enfermedad sistémica con compromiso del sistema nervioso central y del sistema inmunológico, así como de pulmón, riñón, colon y piel, y a quien finalmente se le diagnosticó toxoplasmosis diseminada, a pesar de haber recibido profilaxis con trimetoprim-sulfametoxazol, debido a que el órgano provenía de un donante positivo para toxoplasmosis siendo él un receptor negativo. Se discuten las opciones de profilaxis en nuestro medio.
Abstract We report the case of a 61 year-old male who underwent heart transplantation eight months before developing a systemic condition with central nervous system, lung, kidney, colonic, cutaneous, and hematologic involvement, found to be secondary to a systemic toxoplasmosis despite co-trimoxazole prophylaxis in a previous-to-transplant seronegative patient receiving a heart from a seropositive donor. A review of prophylactic options in our environment is discussed.
Asunto(s)
Humanos , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias/etiología , Toxoplasmosis/transmisión , Trasplante de Corazón , Antivirales/uso terapéutico , Intercambio Plasmático , Complicaciones Posoperatorias/parasitología , Complicaciones Posoperatorias/prevención & control , Recurrencia , Donantes de Tejidos , Viremia/tratamiento farmacológico , Viremia/transmisión , Anticuerpos Antiprotozoarios/sangre , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Toxoplasmosis/prevención & control , Inmunoglobulinas Intravenosas/uso terapéutico , Terapia Combinada , Infecciones por Citomegalovirus/tratamiento farmacológico , Infecciones por Citomegalovirus/transmisión , Progresión de la Enfermedad , Seroconversión , Inmunosupresores/efectos adversosAsunto(s)
Humanos , Peritonitis/prevención & control , Infecciones Bacterianas/prevención & control , Norfloxacino/administración & dosificación , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Bacteriemia/prevención & control , Cirrosis Hepática/complicaciones , Peritonitis/complicaciones , Australia , Infecciones Bacterianas/complicaciones , Estudios Prospectivos , Reproducibilidad de los Resultados , Resultado del Tratamiento , Bacteriemia/complicaciones , Medicina Basada en la Evidencia , Antiinfecciosos/administración & dosificación , Antibacterianos/administración & dosificaciónAsunto(s)
Humanos , Infecciones Bacterianas/etiología , Infecciones por Citomegalovirus/etiología , Trasplante de Corazón/clasificación , Pulmón/patología , Servicio Ambulatorio en Hospital/clasificación , Infecciones por Pneumocystis/epidemiología , Infecciones por Pneumocystis/etiología , Ceftriaxona/administración & dosificación , Factores de Tiempo , Combinación Trimetoprim y Sulfametoxazol/administración & dosificaciónRESUMEN
This study aimed to investigate the synergistic effects of resveratrol and sulfamethoxazole-trimethoprim (ST) on the treatment of mice experimentally infected by Toxoplasma gondii during the chronic phase of the disease considering infection, behavior, and oxidative/antioxidants profile aspects. For the study, 60 mice were initially divided into two groups: uninfected (n = 24) and infected by T. gondii (n = 36). These two groups were later subdivided into other groups and treated with resveratrol (free and inclusion complex containing resveratrol) alone and co-administered with ST: groups A to D were composed by healthy mice and groups E to J were consisted of animals infected by T. gondii (VEG strain). Treatments began 20 days post-infection for 10 consecutive days with oral doses of 0.5 mg kg(-1) of ST (groups B and F), 100 mg kg(-1) of free resveratrol (groups C and G) and inclusion complex of resveratrol (nanoparticles containing resveratrol) (groups D and H), and lastly an co-administration of both drugs (groups I and J). Behavioral tests (memory, anxiety and locomotion) were performed after treatment. Liver and brain fragments were collected to evaluate pathological changes, brain cysts counts, as well as oxidant and antioxidant levels. A reduction on the number of cysts in the brain of animals treated with both drugs combined was observed; there was also reduced number of lesions on both organs. This drug combined effect was also able to reduce oxidative and increase antioxidant levels in infected mice, which might be interpreted as a resveratrol protective effect. In addition, the combination of ST and resveratrol was able to prevent behavioral changes in infected mice. Therefore, the use of co-administration drugs enhances the therapeutic effect acting on a synergic way, reducing the oxidizing effects of the chemical treatment for toxoplasmosis. In addition, resveratrol in inclusion complex when co-administered with ST showed an improved therapeutic effect of ST reducing oxidative damage, liver damage and the number of cysts in the brain of T. gondii infected mice.
Asunto(s)
Antiinfecciosos/administración & dosificación , Antiinflamatorios no Esteroideos/administración & dosificación , Conducta Animal , Estrés Oxidativo , Estilbenos/administración & dosificación , Toxoplasmosis Animal/tratamiento farmacológico , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Animales , Antioxidantes/análisis , Encéfalo/patología , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Quimioterapia Combinada , Hígado/patología , Ratones , Oxidantes/antagonistas & inhibidores , Resveratrol , Toxoplasmosis Animal/patología , Resultado del TratamientoRESUMEN
PURPOSE: To evaluate outcomes and complications of pars plana vitrectomy in patients with epiretinal membrane secondary to toxoplasmic retinochoroiditis. METHODS: Retrospective evaluation of the records of 14 patients who underwent pars plana vitrectomy for epiretinal membrane secondary to toxoplasmic retinochoroiditis. The best-corrected visual acuity, intraoperative and postoperative complications, and macular optical coherence tomography were analysed. All patients received postoperative prophylactic treatment with trimethoprim/sulfamethoxazole. RESULTS: Fourteen patients, 5 men and 9 women, were included. Mean follow-up period after surgery was 6.07 ± 2.64 months. Preoperative mean best-corrected visual acuity was 20/200, and postoperative mean best-corrected visual acuity was 20/60. There were no intraoperative complications. Three patients developed posterior capsule opacification, and one patient developed cataract. CONCLUSION: Pars plana vitrectomy is a safe and effective procedure in patients with epiretinal membrane secondary to toxoplasmic retinochoroiditis, improving both visual acuity and anatomical result on macular optical coherence tomography. The most frequent postoperative complications were posterior capsule opacification and cataract. No recurrences of the disease were recorded.
Asunto(s)
Coriorretinitis/cirugía , Membrana Epirretinal/cirugía , Infecciones Parasitarias del Ojo/cirugía , Toxoplasmosis Ocular/cirugía , Vitrectomía , Adulto , Antibacterianos/administración & dosificación , Coriorretinitis/diagnóstico por imagen , Coriorretinitis/parasitología , Membrana Epirretinal/diagnóstico por imagen , Membrana Epirretinal/parasitología , Infecciones Parasitarias del Ojo/diagnóstico por imagen , Infecciones Parasitarias del Ojo/parasitología , Femenino , Humanos , Complicaciones Intraoperatorias , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias , Recurrencia , Estudios Retrospectivos , Tomografía de Coherencia Óptica , Toxoplasmosis Ocular/diagnóstico por imagen , Toxoplasmosis Ocular/parasitología , Resultado del Tratamiento , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Agudeza Visual/fisiología , Adulto JovenAsunto(s)
Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Espironolactona/efectos adversos , Combinación Trimetoprim y Sulfametoxazol/efectos adversos , Muerte Súbita/etiología , Antagonistas de Receptores de Mineralocorticoides/efectos adversos , Ontario , Espironolactona/administración & dosificación , Estudios de Casos y Controles , Intervalos de Confianza , Oportunidad Relativa , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Factores de Riesgo , Factores de Edad , Interacciones Farmacológicas , Quimioterapia Combinada/efectos adversos , Antagonistas de Receptores de Mineralocorticoides/administración & dosificación , Hiperpotasemia/inducido químicamente , Hiperpotasemia/mortalidad , Antiinfecciosos Urinarios/administración & dosificación , Antiinfecciosos Urinarios/efectos adversosRESUMEN
The aim of this study was to investigate the effects of resveratrol on its free form and complexed with 2-hydroxypropyl-ß-cyclodextrin (HPßCD) when associated with sulfamethoxazole-trimethoprim (ST) on cytokines levels of mice (n = 60) experimentally infected by Toxoplasma gondii. Groups A and E were used as controls (untreated): negative and positive, respectively. The onset of treatment started 20 days post-infection (PI), and it lasted for 10 consecutive days. ST was administered orally in doses of 0.5 mg kg(-1) for groups B and F, while 100 mg kg(-1) was the dose for resveratrol in its free form (groups C - G), inclusion complex (groups D and H), and on free and inclusion complex together (groups I - J). On day 31 PI, blood samples were collected in order to evaluate the cytokine profile. The mice that received drug combination (I and J) showed a significant (P < 0.05) reduction in the number of cysts in the brain compared to other infected groups (E - H). The results showed that mice from the Group E had increased (P < 0.001) levels of pro-inflammatory cytokines, while IL-10 levels were reduced when compared to the Group A. Additionally, there were increased levels of IL-4 and IFN-γ in animals of groups C and D, respectively (P < 0.05). Animals of the Group B showed reduced levels of IL-1, IL-4, IL-6, TNF-α, and IFN-γ (P < 0.05). Mice infected and treated (groups F - J) showed increased levels of pro-inflammatory cytokines along with a reduction of IL-10. Treatment with the combination of drugs (the Group J) led to a protective effect, i.e. reduction in pro-inflammatory cytokines. Therefore, resveratrol associated with ST was able to modulate seric cytokine profile and moderate the tissue inflammatory process caused by T. gondii infection, as well as to reduce parasite multiplication.
Asunto(s)
Antiprotozoarios/administración & dosificación , Citocinas/análisis , Factores Inmunológicos/administración & dosificación , Estilbenos/administración & dosificación , Toxoplasmosis Animal/tratamiento farmacológico , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , beta-Ciclodextrinas/administración & dosificación , 2-Hidroxipropil-beta-Ciclodextrina , Animales , Encéfalo/patología , Ratones Endogámicos BALB C , Resveratrol , Suero/química , Toxoplasma/crecimiento & desarrollo , Resultado del TratamientoRESUMEN
Listeria monocytogenes is a Gram-positive, facultative anaerobic, rod-shaped bacterium that can infect and cause disease in many species. In this case report, we describe a case of L. monocytogenes infection causing sepsis in a sugar glider (Petaurus breviceps). The sugar glider consumed a varied diet consisting of human food items, including cantaloupe. A nationwide outbreak of L. monocytogenes foodborne illness associated with cantaloupes occurred simultaneously with this incident case. In this case, the bacterial strains from the outbreak and glider were genetically distinct. Although rare, veterinarians should be aware of the emergence of foodborne pathogens' ability to infect exotic animals residing in domestic environments.